secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anteris Technologies Global Corp. (AVR)
CIK:        0002011514
Form:       8-K
Filed at:   2025-11-17T23:59:59+00:00
Accession:  0001140361-25-042395
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anteris reports positive 30-day DurAVR THV outcomes in 100 small-annuli patients
--------------------------------------------------------------------------------

- No valve-related mortality and no moderate/severe paravalvular leak at 30 days.
- Mean gradient 8.2 mmHg; effective orifice area 2.2 cm², reflecting single-digit gradients.
- 97% freedom from moderate/severe prosthesis-patient mismatch vs 11-35% in SMART Trial.
- Technical success rate 100% in the last 50 consecutive patient implants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2011514/000114036125042395/0001140361-25-042395-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2011514/000114036125042395/ef20059387_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-042395

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer